More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

DCAT Value Chain Insights

Is the US Food and Drug and Administration achieving parity in inspections of foreign and domestic manufacturers? A recent report by the US Department of Health and Human Services' Office of the Inspector General (IOG) examined the FDA's progress...
DCAT Value Chain Insights

In the latest deal in the specialty pharmaceuticals market, Endo International has agreed to acquire Par Pharmaceutical for $8 billion. What are the implications for the companies and the specialty pharmaceutical market as a whole?DCAT Value Chain...
DCAT Value Chain Insights

The global oncology market is the largest therapeutic area overall and in developed markets. In 2014, this segment reached the $100 billion mark. DCAT Value Chain Insights (VCI) examines the strengths and weaknesses of the global oncology market....
DCAT Value Chain Insights

Risk management is a crucial part of any company's strategic and operational focus. But how does it impact the bottom line? A recent PwC study, surveying senior executives, shares key insight. A recent PwC survey found that almost three-fourths of...
DCAT Value Chain Insights

So how did the pharmaceutical majors fare in the first quarter and what are the key product and pipeline developments? DCAT Value Chain Insights (VCI) examines the latest. First-quarter results are in for Pfizer, Sanofi, AstraZeneca, Bayer...
DCAT Value Chain Insights

The global generic-drug market is undergoing change as consolidation looms among the top players and gains from recent patent expiries lessen. So what is in store for the global generic-drug market? DCAT Value Chain Insights takes an inside look....
DCAT Value Chain Insights

The rankings of the top global pharmaceutical companies and products are undergoing change as mergers and acquisitions, new product launches, and the rise of biologics influence the order of the pharmaceutical industry. Recent proposed merger and...
DCAT Value Chain Insights

Teva Pharmaceutical Industries Ltd. has announced a proposal to acquire all of the outstanding shares of Mylan N.V. in a transaction valued at approximately $40 billion. The move would create a top 10 pharma company with combined 2014 pro forma...
DCAT Value Chain Insights

Led by growth in the oncology sector, high-potency manufacturing continues to be an area of investment for contract manufacturers and suppliers. DCAT Value Chain Insights (VCI) examines recent investment. Growth in the global oncology drug...